Status
Conditions
About
S-1 has been also shown to be an effective drug for palliative chemotherapy in Eastern and Western GC patients. Recently, some case and small-sized studies have been reported on lacrimal drainage obstruction(LDO)caused by S-1.Suggested mechanism of LDO involves direct secretion of S-1 into the tear; thus the concentration of S-1 metabolite in tear is expected to be high in patients who developed LDO than in patients without LDO. We investigate the concentration of S-1 and its metabolites in tear and plasma and find out its correlation with side effects such as LDO. These results will also help us identify patients who are at high risk of developing S-1-associated side effects.
Full description
S-1 metabolites concentration in plasma
factors affecting plasma concentration
systemic adverse effects of S-1 and its correlation with plasma S-1 metabolites concentration
S-1 metabolites concentration in tears
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Central trial contact
Keon-Wook Lee, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal